^
    Back
    Association details:
    Biomarker:RET-TRIM33 fusion
    Cancer:Lung Cancer
    Drug:vepafestinib (TAS0953/HM06) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Nat Cancer
    Title:

    Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

    Published date:
    09/21/2023
    Excerpt:
    Vepafestinib also inhibited the growth of multiple lung cancer patient-derived cell lines harboring RET fusions with different N-terminal partners (CCDC6, KIF5B, TRIM33) and a RETC634W-mutation-positive MTC cell line.
    DOI:
    https://doi.org/10.1038/s43018-023-00630-y